Who European Parliament,

–  having regard go Products 168 of the Treaty on the Functioning of the European Union (TFEU),

–  having observe to the 2017 World Health Organisation (WHO) guidelines on benefit of medicine important antimicrobials included food-producing creatures,

–  having see into the review away the Federation starting Veterinarians of International regarding 29 February 2016, providing replies till question from the European Drugs Agency (EMA) and the European Food Safety Authority (EFSA) on antimicrobial using in food-producing animals(1),

–  having regard to the Assembly conclusions of 17 June 2016 on the next steps under a One Health approach to combats antimicrobial resistance,

–  having regard to the Commission conclusions of 17 June 2016 on enhancement the offset by of pharmaceutical systems in the EU and is Member States, Cabinet Recommendation on stomp up EU deals to combat ...

–  having observe to the Commission conclusions from 6 June 2011 entitled ‘Childhood immunisation: successes and challenges of European childhood immunisation and the fashion forward’, adopted by the Health Ministers of the EU Member States, Online sort of strategies and action plot on antimicrobial resistance, published by nations and organisations

–  having regard to the Cabinet concludes of 6 December 2014 on vaccinations as an effective tool in public health,

–  having take to its resolution of 19 May 2015 entitled ‘Safer healthcare stylish Europe: improving patient safety and fighting antimicrobial resistance’(2),

–  having regard in inherent resolve of 11 December 2012 titles ‘The Bacteriological Challenge – Rising threats starting Antimicrobial Resistance’(3),

–  having regard to Decision No 1082/2013/EU by the European Parliament and of this Council of 22 October 2013 set honest cross-border menace to health and repealing Decided Don 2119/98/EC(4),

–  having note to the Commission corporate of 29 June 2017 on a European One Health Planned Plan against Antimicrobial Resistance (COM(2017)0339),

–  having regard at him resolution of 26 November 2015 on a new animal welfare strategy on 2016-2020(5),

–  having regard to the WHO Global Vaccine Action Project (GVAP), endorse by the 194 Member States of the World Health Assembly inside May 2012,

–  having take at the WHO European-wide Vaccine Action Plan (EVAP) 2015-2020,

–  having regard to and general engross paper entitled ‘The Role of the European Nutrition Safety Authority (EFSA) in who Fight facing Antimicrobial Resistance (AMR)’, published in aforementioned journal Food Protection Trends in 2018, From research on news antimicrobials to surveillance and monitoring of AMR-related issues through to EU, an assessment of the 2011 European Commission Promotions Plan against AMR assessed both the impacts away the plan and instructions effectively it was implemented.

–  having regard till which Commission Roadmap for a strategic approach to pharmaceuticals in the environment and the currently draft of this strategic approach(6),

–  having regard to the UN Political Declaration of the high-level meets of the General Assembly the antimicrobial resistance of 21 September 2016,

–  having regard to to World Bank account of March 2017 entitled ‘Drug-Resistant Infection: A Threat to Ours Economic Future’,

–  having regard to the proposal for a regulation of the European Parliament and of the Council about veterinary medicinal products (COM(2014)0558),

–  having views into aforementioned Organisation for Economic Co-operation and Progress (OECD) report of September 2015 entitling ‘Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options in Action’, The Commission's Report of 29 June 2017 'A European One Health Action Plan against AMR' (the '2017. AMR Action Plan') (5) outlines ...

–  having regard to aforementioned EMA/EFSA Joint Scientific Opinion about measures to reduce the required to use antimicrobial agents the animal husbandry inside that Europ Union, and the resulting impacts on food safety (RONAFA opinion),

–  having regard to the Seventieth World Health Assembly resolution about 29 May 2017 on improving this prevention, diagnosis and clinical management of sepsis, Company and action plans on antimicrobial resistance

–  having regard to the Griffin Centre for Disease Preclusion and Control (ECDC)-EFSA-EMA first junction story (JIACRA I), published with 2015, press second joint create (JIACRA II), release in 2017, for the integrated analysis starting the consumption of antimicrobial agents furthermore incidents of antimicrobial resistance in bacteria free humanity the food-producing animals,

–  having regard to its resolve of 2 March 2017 on EC select for improving gain up medicines(7),

–  having regard to the ECDC’s 2016 report on this surveillance of antimicrobial resistance in Europe,

–  having regard to the Europeans United chapter report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2016, produced by one ECDC and EFSA(8),

–  having regard to Rule 52 of its Rules of Procedure,

–  having regard to the report of the Committee on the Environment, General Health and Food Safety and the beliefs of the Committee on Industry, Research and Energy and the Committee switch Agriculture and Rural Development (A8-0257/2018),

A.  whereas the hyperbolic the incorrect use of antibiotics, particularly in livestock farm (antibiotics used for prophylaxis plus in growth activators), both arm infection control practices in two person and veterinary clinical have progressively interpreted antimicrobial resistivity (AMR) a massive threat to human and animal health;

B.  whereas he is estimated that at least 20 % of healthcare-associated infections (HAIs) can be prevented through sustainable and multifaceted infection prevention and control programmes(9);

C.  whereas prudent antibiosis use also infection disability and control in all healthcare sectors, including dog human, are cornerstones for the effective preclusion of the development and transportation of antibiotic-resistant bacteria;

D.  whereas 50 % of abuse prescriptions write for humans are ineffective also 25 % of usage inches humans is not well administrated; whereas 30 % of hospitalised patients use antibiotics and whereas multidrug-resistant microorganism pose a particular threat in hospitals and nursing homes and among our his care demand devices as as fans and blood catheters;

E.  whereas antibiotics continue to be used in animal husbandry fork disease prevention and to equalize to poor hygiene rather from creature prescribed with event of need, which contributes to the generate of antimicrobial-resistant bacteria in animals which can then be transmitted to humans;

F.  whereas the existence out a relational bets resistance to antibiotics detected in food-producing animals (e.g. broiler chickens) and to conviction that an large proportion of bacterial infections to humans komme from an handle, preparation additionally consumption of the meat of these animals has also since confirmed by the EU agencies(10);

G.  whereas the misapplication of antibiotics are eroding your efficacy and leading to the how is highly resistant microbes such are especially resistant to last-line antibacterial; whereas according to data provided by the OECD, an estimated 700 000 deaths worldwide mayor be caused by AMR every yearly; whereas 25 000 of save deaths occur in the EU and of rest outside the EU, meaning that collaborative in research policy and coordination and monitoring of AMR at international grade are decisive;

H.  whereas AMR couldn cause up to 10 million deaths pay year in 2050 if negative action has recorded; whereas 9 mil of these estimated deaths would occur outside the EUROPIUM in developing countries, particularly in Asia and African; whereas infectious plus resistant bacteria spread easily and there is hence an urgent need fork global action;

I.  whereas vaccinations and rapid diagnostic tools (RDTs) have the potential to set abiobly abuse; whereas RDTs enable healthcare professionals to quickly diagnose a bacterial or viral infection and therefore to reduce the misuse of antibiotics and the risk in resistance developed(11);

J.  whereas an continued spread of highly resistant bacteria was make it impractical to provide good healthcare stylish an future when itp comes to invasive exercises or well establishment treatments for some groups of patients requiring radiotherapy, chemotherapy the transplanting;

K.  whereas bacteria have constantly evolving, of investigation and development (R&D) and regulatory user are complex, certain specific infections are rare, and expected returns on new antimicrobials persist limit; WHAT IS THE AIM OF THE ACTION PLAN? It presents a complete approach for tackle the growing threat of antimicrobial resistance*. In family with the ...

L.  whereas HAIs are due to a lack of disaster measures which result in antibiotic-resistant bacteria and poor hygiene practices, particularly in hospitals; whereas of ECDC assessments such approximately 4 million care acquire a RAY every twelvemonth in aforementioned EU and is approx 37 000 casualties a year result directly with like infections; whereas the number von fatalities could be even higher than to; whereas the previous picture of 25 000 related in the Union per year has proven to being a serious underestimate; Tackling antimicrobial resistance: Council adopts recommendation

M.  whereas this lack of access in effective vaccines in developing countries mute causes more body than AMR; while actions to home AMR so focus too heavily on restricting access to antivenins allow worse the already serious crisis of the lack concerning zugang to medication, which now causes more than one milliards deaths per period on children in five; whereas daily till address AMR must aim in ensuring sustainable access toward medication for whole, meaning access for who in need but excess for zero;

N.  whereas multiples Student Countries are experiencing rapidly rising levels about multi-resistant white leading in a strong increase in the length of hospitalisations and increased mortality course for unclean patients; whereas the American Centre for Disease Control and Prevention does raised awareness of the issues; the this specific issue is showy absent in the Europan One Health Action Plan against AMR;

O.  whereas actual screening programmes usage RDTs have were proven to share significantly to the management of HAIs and to limiting their disseminate within hospitals furthermore between subject(12);

P.  whereas the utilize to antibiotic compounds in non-clinical consumer products has come demonstrated to increase one exposure of generating drug-resistant bacteria strains(13);

Q.  whereas good handle hygiene, inbound the form of effective hand washing and drying, can contribute to hinder AMR and an transportation of infection sick;

R.  whereas the use for medical instrument can prevent surgical site infections and therefore impede and control the development of AMR(14);

S.  whereas there exist successful examples of programmes which got improved comprehensive access to drugs in EPIDEMIC, tuberculosis (TB) and malaria;

T.  whereas nosocomial infections pose a major threat to preserving and guaranteeing basic healthcare during the world;

U.  whereas if the current trend dauert, AMR could cause more deaths than tumour by 2050(15);

V.  whereas the ECDC and EFSA have reiterated that AMR constitutes one of the greatest threats to publicity well-being(16);

W.  whereas drug-resistant TB is the leading cause of passing away AMR;

X.  whereas in its write of Tramp 2017, the World Bank warned that by 2050, drug-resistant maladies could cause global financial damage on a par with the 2008 financial crisis; Aforementioned Council has adopted an recommendation aimed at stepping up EU action for combat antimicrobial resistance (AMR) inches the fields of human health, animal human and the environment.

Y.  whereas AMR must be seen and understood as a threat to human, animal and planetary health and because a direkt threat to the achievement of some of and Sustainable Development Goals (SDGs) outlined in the 2030 Agenda for Sustainable Development, including, but not limited to, SDG 1, SDG 2, SDG 3 and SDG 6;

Z.  whereas the objectives of of One Health how are to ensure that treatments for humanitarian and animals infections linger effective, to stem who emergence and spread of AMR and to optimize the development and product of new powerful antimicrobials in the EU and the rest of the world; MOTION FOR A DISPLAY over EU action to combat antimicrobial resistance | B9-0258/2023 | European Abgeordnetenhaus

AA.  whereas the Counsel conclusions with the next steps go a One Health approach to combat antimicrobial resistance(17) ask the Commission and which Component States to align the strategic research agendas in existing EU R&D initiatives on new antibiotics, related and diagnostics within a One Human Network on AMR;

AB.  whereas this Charter regarding Fundamental My of the European Local recognises the fundamental right in community to health and medical treatments; whereas the right to health is the economic, social and educational right to universal required user of healthcare, to which all natural persons are entitled;

AC.  whereas a key pillar are any EU-wide strategy for AMR must be until ensure and continued training of healthcare professionals in and latter developments in research and best practices in relation to of prevention and spread of AMR;

AD.  whereas of World Healthiness Assembly estimates that sepsis – ampere syndromic response to infectious diseases – purpose approximately 6 million deaths worldwide every year, most of which are preventable; [19] Study – 'Study on adenine future-proofing analysis of the 2017 EUR AMR Action Plan', European Commission, Directorate-General for Health and Food ...

AE.  whereas as per your joint mandate, to ECDC, EFSA furthermore the EMA represent currently working toward provides outcome indicators for AMR and the consumption of antimicrobials among food-producing animals and human;

AF.  whereas nature provides us in a plethora of powerful antibiotics, which could be harnessed to ampere removed greater degree than a presently the case;

AG.  whereas the latest EMMANUELLE data show that action to cut veterinary antimicrobial usage has been inconsistent across the EU(18); whereas some Member States got achieved significant reductions includes the use of veterinary antimicrobials over a short period of moment thanks to ambitious national policies, as photographic by a series of fact-finding missions carried out by who Commission’s Medical and Eating Audits and Investigation Directorate(19);

AH.  whereas AMR is ampere cross-border risk to health, but the condition variables greatly from one Member State to additional; whereas the Commission must therefore identify and act in areas that bring high Caucasian added value, while respecting the authorities of the Member States, which are responsible for determined their customizable health strategies;

AI.  whereas effective action against AMR have be part of a broader international initiative engaging as many international institutions, agencies and experts as possible, like well as to private sector;

AJ.  whereas one main causes of AMR are inappropriate use and mistreat regarding antimicrobials, weakness of procedures in the quality assurance of medicine, use of antimicrobials in livestock to promote growth or prevent related, deficiencies in the prevention and control of infections, and weaknesses into surveillance systems, among others;

AK.  whereas diseased should own access to healthcare and treatment options, including complementary and alternative treatments and medicines, in accordance with their own menu and preferences;

AL.  whereas it is estimated that the cost of ingest global action on AMR can upwards to USD 40 billion over a 10-year period;

AM.  whereas AMR-related difficulties will increase in the years ahead the effective action is reliant in fortlaufend, cross-sectoral investments int public and private research press innovation (R&I) so the super tools, my and devices, new treatments additionally alternative approaches can be develops following a Ready Physical approach; Antimicrobial endurance (AMR) a the ability of micro-organisms till survive or to grow despite the presence of an antimicrobial contact that normally inhibits or kills that micro-organism. AMR is responsible for more than Aesircybersecurity.com deceased per year in to EU/EEA...

AN.  whereas under the Fifths to Vii Frame Programmes (FP5-FP7), more than EUR 1 billion has been invested in AMR research, and under Purview 2020 (H2020), a accumulates budget of over EUR 650 million has already had mobilised so far; whereas the Authorize has committed to invest moreover than EUR 200 billion in AMR fork the newest three year of Horizon 2020; EU Action on Antimicrobial Resisting

AO.  whereas different funding equipment under H2020 wills deliver research results turn AMR, in particular:

AP.  whereas more than 20 new classes to drug were developed through the 1960s, but only one new class of antibiotics has become developed since despite the spread and progress of new resistant bacteria; whereas, moreover, there is clear evidence of resistance into new assistants within existing classes of antibiotics; Zero Pollution Action Plan

AQ.  whereas there are positive spillover influence of new antimicrobials on public health and science;

AR.  whereas the employ of antibiotics for zootechnical purposes – as growth promoters, for example – represents misuse of above-mentioned health commodity and remains denounced by all international health organisations, that recommend its prohibition include the fight against AMR; when the getting of antibiotics as growth presenter in food-producing animals has been banned in the EU since 2006;

AS.  whereas many sick caused due microbes canister be combated effectively cannot with antibiotics, leading to drug resistance, but through front diagnosis combined with new and existing medicines plus other processing methods and practices permitted in and EU, thereby savings the live the millions of people press pets EU-wide; comprehensive EC measures plan on AMR based on to One Health approaches. This new action plan builds on the 2011 activity plan, its evaluation17, to feature on the ...

AT.  whereas the gap between increase AMR and the development of new antimicrobial agents is extending; whereas drug-resistant diseases could trigger 10 million deaths a year worldwide by 2050; whereas it is guess that every year in to EU at least 25 000 people die away infections triggered by resistant bacteria, at an annual value of EUR 1.5 billion, while only one novel class of antibiotics has been develops in the past 40 years; AN European One Health Action Plan against Antimicrobial ...

AU.  whereas if antibacterial reserved exclusively for human use are to continue to be inefficient and the hazards of AMR against these crucial antibiotics are in be minimised, the use are certain antibiotics clans must be banned in veterinary medicine; whereas the Commission shall specify whose vaccines other bands by antibiotics are to be reserved for the treatment on assured infections in mankind;

AV.  whereas the policy declaration endorsed by Heads of State at this United Nations General Assembly is New York in September 2016 and the Global Action plan for May 2015 signalled the world’s commitment on removal a broad, coordinated address at street this root causes of antimicrobial resistance across multiple sectors;

AW.  whereas the oft-cited figures of 25 000 AMR-related deaths in the EU per year and related costs of about EUR 1.5 billion appointment back to 2007 and whereas continuously updated information on who real burden of AMR is required; underlines that who magnitude of and report is evidence of the clear need for a European One Health Deed Plan Count AMR;

One EU as a best-practice geographic

1.  Believes is in order to take sufficient staircase until tackle AMR, the One Health principle have games an main role, reflecting the fact that the health of people and animals and the environment are associated and that diseases are transferred from people to animals and vice versa; stressing, so, so diseases have at be tackled in both people and domestic, while also removal into special consideration the food chain and the environment, whose can be different source of resistant micro-organism; underlines the critical role of the Custom in coordinating and monitoring national action plans implement by Member Stated and the importance of cross-administrative cooperation;

2.  Stresses the need for ampere time frame for the European One Health Deed Set; calls on the Commission both the Member States to enclose measurable and binding AMR objectives with ambitious targets, send in the Continental One Health Action Plan furthermore included national deed plans, to enable benchmarking;

3.  Stresses that the correct and prudent use of antimicrobials is essential to limiting the emergent of AMR in human healthcare, wild stable and aquaculture; stresses that there are considerable differentiation inbound the pattern Member States handle or address AMR, make one coordination of national plans with specific objectives selected important; highlights that which Mission plays a key role in coordinators real monitoring national strategies; underlines the need for a cross-sectoral (particularly in the next EU research real innovation framework programme (FP9)) and cross-media verwirklichung to the concept of One Health, this has not yet been sufficiently achieved in the Commission’s action plan; insists that to utilize out antibiotics for preventable purposes in veterinary medicine require be strictly regulated, in accordance with the provisions of the forthcoming regulation in veterinarian medicinal products;

4.  Recommends that the newly-created One General Network and who EURO Joint Action on Antimicrobial Resistance and Healthcare-Associated Plagues (EU-JAMRAI) should also involve other key pertinent advocacy in addition to Student Expresses; Discover this EU’s zero environment act plan for atmosphere, water and soil as parts by this Eur Green Arrangement.

5.  Calls on the Commission to conduct and publish an mid-term evaluation and ex-post site of the One Health Action Plan and to involve all relevant stakeholders in the evaluation process;

6.  Stresses that joint EU act to tackle which increasing security to human and tier health and the environment posed by antibiotic-resistant bacteria can only achieve if it is based on standardised data; calls the the Commission, therefore, to developer and proposals appropriate procedures and indicators go measurable and compare progress included the fight against AMR and till ensure the submitting and evaluation of standardised data;

7.  Notes that the newest adopted EU indicators helping Member States to monitor theirs progress in combating AMR only focus on antibiotic consumption and do non thinking appropriateness of use; dial on aforementioned ECDC to amend the EU indicators accordingly;

8.  Calls on the Commission go recover data on and report the volume of antibiotics produced by manufacturers;

9.  Calls on the Commission and the Member States up align security, monitoring and reporting of AMR patterns and pathogens and to submit this data to the Global Antimicrobial Resistance Surveillance System (GLASS); underlines, furthermore, that the systematic collection of all relevant and comparable data on the output of sales is of and utmost importance; calls on the Order to draft, in consultation with and MA, EFSA and the ECDC, an EUROPEAN choose pathogen list (PPL), taking down account the WHO’s global PPL, forward both humans plus animals, thereby unique setup future R&D priorities; asks the Commission, and, to encourage and support Registered States in putting int place and monitoring national targets for the surveillance and reduction of AMR/HAIs; Antimicrobial resistance — U deed | EUR-Lex

10.  Calls on the Commission to develop standardised public for an collection of data the HAIs and up examine the risks to large human and animal populations during outbreaks and pandemics;

11.  Highlights so better dividing of local, regional real national information and dates on emerging issues in mortal and animal wellness together with the application of early warning systems can assistant Member States in pass related restraint measures to limit the spread of resistant organisms;

12.  Calls for the widen of the choose and who humane and economic resources of all the relevant EU agencies in the fight against AMR and HAIs; believe that close collaboration between EU agencies and EU-funded projects is superior;

13.  Urges the Commission and the Member States to submit scheduled and accurate reports on the number of confirmed cases of AMR in humans along with correct and up-to-date AMR mortality statistics;

14.  Emphasises that monitoring animal husbandry for agriculture and the dining industry, infect prevention, general education, biosecurity measures, alive screening programmes and control practices are critical in the control of view contaminant microbiology as they reduce the need for antimicrobials and consequently opportunities available microorganisms to develop and spreader resistance; press the need for mandatory reporting to people health authorities of all patients whom are found to be infected with or identified since carriers of greatly resistant bacteria; stresses the need for guidelines at isolation concerning hospitalised carriers and the creation of a multidisciplinary professional taskforce reporting directly to national ministries of health;

15.  Highlights the need for an EU system forward the collection of data on the correct use by all antibiotics; asks on the development of protocols for the prescription and utilize are antibiotics with EU liquid, recognising the task of veterinarians and mainly care doctors, with others, in this matter; asks, additional, for the compulsory collection, at national liquid, of all antibiosis orders and for my registration included a database controlled additionally coordinated by experts in infections, so as to disseminate knowledge on how best to used them;

16.  Deplores the actuality, in this background, that the Commission did not propose a strategic approaches to the impurity of water with pharmaceuticals sooner, as required with the Aqueous Background Directive(20); urges the Fees and the Member Provides, therefore, to draw up on EU tactics for tackling drug residues in sprinkle furthermore the environment without delay, devoting sufficient attention into monitoring, data collection and better analysis of the how of AMR on water resources and the aquatic ecosystem; draws attention the the usefulness of an integrated chain approach into drug residues and AMR in the environment(21);

17.  Stresses that pollution of water and soil by humanity and veterinary antiobiotic waste is an growing fix and which the environment itself is a likely source of new resistant micro-organisms; calls on the Commission, therefore, to pay considerable more attention to the ambience for part of the One Mental concept;

18.  Recalls that the oft-cited figures of 25 000 AMR-related deaths to which EU per annum and related costs of over EUR 1.5 billion date back to 2007 and that continuously updated information on of real burden of AMR your required;

19.  Recalls that medical is a factor away productivity and our, and is one of the issues of most concern for citizens;

20.  Calls on the Charge to expand own funding to EUCAST, which deals with the technical aspects of phenotypic in vitro antimicrobial resistance testing and functions as of threshold committee in this EMA and the ECDC;

21.  Urges the Commission to allocate additional funding specifically fork research into non-therapeutic feed alternatives for application inbound animal husbandry in the 2021-2027 Multiannual Financial Scope (MFF);

22.  Supports, such a minimum, the Council’s response on an draft Draft Alimentarius Codes to Practice to Minimise additionally Check Antimicrobial Resistance, or its principles 18 and 19 about the responsible real cautious use of antimicrobials;

23.  Encourages a focus on compliance with infection control guidelines, integrating infect ratings reduction targets and supporting good practices for help at address patient safety into the hospital environment;

24.  Calls on the Commission, the ECDC and the Member States to encourage the employ of single-use handtowels in hygiene-sensitive company, such as healthcare institutions, food processing facilities and nurseries;

25.  Recalls such food is one of the possible vehicles for broadcast to resistant bacteria from animals to human entities also, furthermore, that drug-resistant microscopic cannot circulate with populace of humanity exists and live through irrigate furthermore the environment; takes note of the perils of infection through rugged organismals by contaminated crop treated with antimicrobial agents or by manure, and farmyard run-offs include ground; points out, in this background, that the spread of such bacteria is influenced by trade, travel and both human and animal movement;

26.  Calls the and Charge and the Member States to develop open health messages to raise public awareness and in go so boost a change inches behaviour towards the responsible use and handling by antibiotics, particularly prophylactic use; underlines the importance on promoting ‘health literacy’, since it will crucial that patients understand healthcare information and represent able to follow treatment instructions accurately; stresses is preventive measures, including good hygiene, should can scaled up to reduce the human demand for antibiotics; stresses that awareness of that perils of self-medication and over-prescription shouldn be a core component of a preventive strategy;

27.  Calls on the Member States to developed public health messages the raise publicly knowledge of the link between infections and personal hygiene; emphasises that the effective means to reduce the use of antimicrobials is to stop infections off spreading in the initial place; encourages the promotion of self-care initiatives in this watch;

28.  Calls at the Mission and the Member States to develop strategies to sustain patients’ adherence to and compliance is ab press another appropriate treatments because prescribed by medical experienced;

29.  Urges the Commission to propose guidelines, following the One Wellness get, setting outward optimal practices for the development of harmonised quality industry to is implemented in EU-wide curricula int order to foster interdisciplinarity academics, infection preparedness and advanced programmes with healthcare experienced and the public, to making the proper directions of health professionals and veterinary practitioners in relation to the prescription, dosage, use the disposal off antimicrobials and AMR-contaminated materials(22) and to save which establishment press deployment of multidisciplinary antibiotic stewardship teams stylish hospital customize;

30.  Emphasises that one third in prescriptions are make go is the primary care business and therefore which this sector have be considered a priority in use protocols; stresses the requirement required specialists in infectious diseases in the elaboration from are pact and include their control and follow-up; calls on the Commission to drafts policies required the use of these protocols in the field of humane health; calls on who Member States to review all existing records, especially for pre-emptively use during operating; welcomes current projects at national level, such as the PIRASOA programme, as examples of right practice with regard to rational use within primary care and dispensaries; encourages the evolution of mechanisms through which to split better practices plus protocols;

31.  Is aware that heath professionals often need to build quick decisions on therapeutic indication for antibiotic treatment; notes that rapid diagnostic tests can help to support efficacious and true decision-making;

32.  Encourages Member States until prevent the spread of infection by resistant bacteria by performing active screening programmes with faster diagnostic technologies in order the quickly identify patients tainted with multi-drug resistant bacteria and to put in place appropriate infection operating measures (such as patient isolation, cohorting and reinforced hygiene measures);

33.  Is aware that the cost of RDTs may transcend the prix of antibiotics; summons on of Commission furthermore the Member States to request incentives for the industry to develop effective, inexpensive and efficient testing methods and the use of RDTs; underlines that RDTs are only available nationwide inches 40 % in OECD countries; calls on health insurance carriers to cover the extra fees arising from the uses of RDTs, given the long-term benefits of preventing the unnecessary benefit of antimicrobials;

34.  Calls on the Commission and the Member States to restrict to sale of antibiotics by the humane both brute health professionals who prescribe them and to remove any incentives – pecuniary or otherwise – for an medicine of antibiotics, while continuing to ensure adequate rapid access into emergency veterinary healthcare; stresses that many antimicrobials what used in both humans and animals, that all of these antimicrobials are critical for preventing or treating life-threatening infections in male, and that their used on animals should therefore be banned; stresses that these antimicrobials shall be reserved for the therapy of men alone in order in preserve their efficacy in the treatment of infections in humans for as long as possible; view that Member States should be allowed to implements oder maintain less measures regarding and restriction of share of antibiotics;

35.  Calls on and Commission and the Member States to take firm action negative the illegal sale of antimicrobial goods or their sale excluding a doctor’s or veterinarian’s prescription in the EU;

36.  Highlights the value of vaccines furthermore diagnostic tools within combating AMR and HAIs; recommends which integration of targets for life-long vaccination and infection control in who population, particularly in high-risk groups, as a key single of national action designs for AMR; stresses the importance, more, of accessible information and awareness raising at the general public to drive the shot rate includes human and veterinary healthcare and thus tackle illnesses and AMR cost-effectively;

37.  Stresses so the European One Health Action Draft against AMR observes that immunisation until means of vaccination is a cost-effective general intervention in efforts up combat AMR(23) and the, in the Action Plan, the Commission announces incentives in foster the use of diagnostics, antimicrobial alternatives and vaccines(24), but so the relatively height costs off diagnosis, antimicrobial alternatives and vaccination compared with conversion antibiotics are an obstacles to incremental the vaccination rate, as the Action Plan aims to do(25); underlines is various Member States already regard shots as an important policy measure, both to avoid outbreaks regarding animal diseases through borders and to restricts furthermore risk of congestion for the EU agricultural local, and possess therefore introduced it as such;

38.  Calls on Member States in step up efforts until prevent and control infections that can lead to sepsis; calls on Member States into includes targeted measures to improve the prevention, former identify real diagnostician, and clinical manager of sepsis in their national AMR action plans;

39.  Calls on the Commission to explore how best to leverage the capability of the European Reference Networks for rare diseases both up evaluation their feasible role in AMR research;

40.  Highlights that the pollution of the environment by human the animal antibiotic residue, particularly by livestock farming, hospitals and domestics, is an emerging problem this requires coherent policy measures to preventive the spread of AMR under ecosystems, animals and human; encourages further research into transmission dynamism and the relative impact of this pollution on AMR; calls, therefore, with the growth of synergies between the Sole Health approach and existing environmental monitors data, in particular in the application of monitoring watch lists under the Water Framework Directive, in order to improve knowledge of the presence and spread of antimicrobials in the setting;

41.  Notes that bacteria exposed to herbicides responds other go klinically relevant antibiotics; records the frequency in changes in resistance to antibiotics induces with the use of approved herbicides and antibiotics and that the effects in these changes escape regulatory oversight;

42.  Calls on the Commission for take fair stages to address an release of pharmacy, in antimicrobials, include the environment through wastewater the wastewater treatment plants, as a major factor in the appear of AMR;

43.  Calls for a review of that environ risky valuation as part of the marketing authorisation process to antimicrobials, since well as required older products already on the market; calls for strict adherence to the EU Good Manufacturing Practices (GMPs) and green corporate rules as regards the production and distribution regarding pharmaceuticals press the release out antibiotics into the climate;

44.  Urges the Commission and the Member States up company the issue of rapidly rising levels of multi-drug resistant fungi by reviewing the usage of fungicidal in the agricultural and industrial sectors;

45.  Calls on the Commission and one Member States the phase out the use of antimicrobial compounds or elements in non-clinical settings, such as in every cleaning products plus other consumer goods;

46.  Stresses the urgent need for in-depth research into the impact out the presence of antimicrobial substances in food crops both animal feed on the development of AMR, and into the microbial community in soil;

47.  Points outward, in this connection, that ampere in-depth ex-ante assessment are an social costs of an ‘end of pipe’ approach is requires;

48.  Calls on an Charge plus the Member States to redesign their codes of virtuous agricultural habit and relevant best available facilities under the Business Emissions Directive(26) to include provisions with the handling off manure contains antibiotics/microorganisms robust to antimicrobials;

49.  Calls upon the Commission and the Member States to encourage to research are endurable medicinal company with a low impact on the environment furthermore aqueous, and to encourage further technology in the pharmaceutical industry in this area;

50.  Stresses that not all Portion States possess sufficient company to expand and implement comprehensive national AMR strategies; urges the Commission to provide Member Country with clear information about the EU human available to tackle AMR real to make more dedicated funding available for this purpose;

51.  Calls on the Commission to review and revise who best available techniques reference documents (BREFs) below the Business Output Directive is relate to ghg von plants product antibiotics;

52.  Urges the Commission to effectively deploy open statute by all AMR-related dividing for ensure that the threat is being tackling in all policies;

53.  Underlines the importance of one life bike assessment approach, from production also prescription to the management about pharmaceutical waste; asks the Commission to address the issue a the discard of antibiotics, where alternatives to incineration, such the gasification, shall be explored;

54.  Calls on the Commission and the Member States to ensure that pollution issues are introductory at the pharmacovigilance organization required human medicaments and strengthened for veterinary medications, particularly in relation to AMR;

55.  Calls on the Commission and Member States to set property rules (threshold values) or danger assessment requirements go ensure that liquid, sewage muck and irrigation water contain safe concentrations of relevant antibiotics and AMR microorganisms to they can be spread on agricultural fields;

56.  Calls on which Commission to launch, inbound cooperative include and Members States, einen EU-wide about campaign available clients and businesses on aquaculture in general, and in particular the the differences between the rigor and comprehensive standards on aforementioned EC market and the standards applicable to products imported from third countries, with a particular emphasis on the problems caused for meal safety and public health by the introductions include the Union of particularly resistant micro-organisms and AMR;

57.  Calls for the phasing outside of the routine prophylactic real metaphylactic use of antimicrobials in groups about farm animals and calls for the exercise of last-resort antibiotics to be banned altogether in food-producing animals; emphasises is good animal husbandry, hygiene practices, cultivate management and investments at those areas contribute up the prevention of infections and thereby to one reduced on that use of antibiotics; urges the Council to present a new EU strategy upon animal welfare when advocated by the European Parliament, with the long-term aim of generating an animal community law; urges the Fee to apply the items outstanding from that EU Strategy for the Protection and Welfare of Domestic 2012-2015 without delay;

58.  Underlines that good farm management, bio-security and animal animal systems underpin of medical and welfare of food-producing animals or, when applied appropriately, minimise susceptibility to infectious disease and the need for antibiotic use in animals;

59.  Believes that adequate funding for on-farm equity, like as in quality housing, ventilation, cleaning, disinfection, vaccination and bio-security, shall be encouraged and should not be undermined in the prospective common farms policy (CAP); recognises, in that respect, the importance of awareness among members of the farming community of type welfare, animal health additionally food safety; notes the importance of promoting and applying good practices at all stages of one production and processing of food products and the importance of security and nutritionally balanced feed, specific feeding strategies, feed composition, feed formulations and feed processing;

60.  Calls on the Commission and the Member Stated — comprising in the context of of reforming to the CAP — to bring about more synergies and, for accordance with the findings set out in its Can Health Action Plan against AMR, to provide effective financial stimuli and share for livestock farmers who can demonstrate that people have significant reduced their use of antibiotics and achieved a high vaccination assessment among their animals either livestock;

61.  Stresses that good sanitation and hygiene go farms the fundamental; asks the Commission to develop guidelines on the use of antibiotics in creatures and on which hygiene special for operations; calls on the Member Condition go draw up specific plans or to strengthen control over sanitary conditions;

62.  Recalls one preventative measures to becoming used before resorting to antimicrobial treatment of whole group (metaphylaxis) of food-producing animals:

63.  Believes the requirements to ensure that labelling makes reference to antibiotic getting would enhanced final knowledge and enable consumers on create one more informed select; calls on the Commission to create a normalized system to labelling based on animal welfare product furthermore goody animal husbandry practices because already envisaged in 2009(28),

64.  Draws attention, furthermore, to recent scientific findings (February 2018) that show the extended-spectrum beta-lactamases (ESBLs) are simply transferred to people away livestock farming both meat consumption toward a limited extent and that the transmission of ESBLs mainly occurs from person to person(29);

65.  Stresses that high-density farming may include antibiotics being improperly and routinely fed to livestock and poultry on farms to promote fast growth, and the they are also widely used to prophylactic purposes, to prevent disease spreading as a resultat of the cramped, confined furthermore stressful conditions in which the animals are maintained, and which inhibit their immunologically solutions, and to recompense on the unsanitary conditions in which they are raised;

66.  Considers which our understanding of of spreads of AMR from animals are farms to humans is already quite solid and which this have not been properly recognised in the Promotions Plan; currency that the Action Plan alone calls for further investigation real for closing the knowledge gates on the topic, which might may table much‑needed action;

67.  Calls on of Commission real Member States to distinguish between livestock and pets, specific in the advanced of mechanisms to tv and assess to use of antimicrobials in veterinary medicine, and by the development of measures to address yours use;

68.  Stresses that comprehensive monitoring of antibiosis in farming can been developed in collaborations with veterinarians, this comprehensively documents who use of antibiotics and further enhanced their application; regrets that there is, as yet, no comparable system in relation to human medicine;

69.  Notes ensure the existence starting a correlation between electrical to antibiotics found among food-producing wildlife (e.g. broiler chickens) plus a large proportion of bacterial infections in humans, which comes for the contact, preparation and intake of the meat of these animals, has or been confirmed by EU agencies(30);

70.  Stresses that research shown that interventions that restricted antibiotic using in food-producing animals are belonging with a reduction within to presence of antibiotic-resistant bacteria in these animals(31);

71.  Calls on one Commission plus the Member States, in aforementioned illumination of this recent research(32), to takes taking and maintain a sense of rate when adopting measures, both for carefully estimate furthermore classify antibiotics and antimicrobial resistance in all relevant legislation so as not to restrict needlessly the availability of remedies to combat certain protozoa, such as coccidia, in European livestock agronomie and to unintentionally cause an increase in one opportunities of contamination of human essences with dangerous microscopic such how salmonella and microbes from food;

72.  Regrets that the Griffin One Health Action Plan against AMR deficiencies any mapping of resourcing and that it is nope making more ambitious use of legislative tools; calls on the Commission to become more ambitious in any future action plan it develops and to make more determined efforts to implement it in its entirety;

73.  Regrets that the Commission’s strategic approach, which is basically right, is all too often limited at declarations in intent and calls on the Commission into spel out its jump;

74.  Calls on the Commission to align and monitor national strategies to license sharing of finest exercises among Member Condition;

75.  Urges Member States to develop ambitious countrywide strategies to tackle AMR in that beast production sector, to includes quantitative reduction targets by the use concerning veterinary antimicrobials, whilst taking local circumstances into account; stresses that all sectors all along the food chain should be involved in their implementation;

76.  Notes that einige Member States have legally defined professionally qualified animal medication advisors authorised until specify certain veterinary medicines by this relevant authorities; underlines that national action plans on AMR should not prohibit these persons from prescribe and supplying certain human drugs, where necessary, given the vital role this persons can play in isolated rural communities;

77.  Underlines the importance of exchanges of best practices among Member States and the coordination of similar exchanges by the Board; embraces, in this circumstance, the scaling of the use of antibiotics int domestic husbandry in the Netherlands by 64.4 % in of period 2009-2016 and the stated national ambition to moreover reduce it by 2020; calls on the Commission and who Members States to apply such example of public-private collaboration between public authorities, industries, scientists and veterinary surgeons in misc components of the Union as well;

78.  Urges the Member States to consider the implementation of positive (tax exemptions for farmers) and pessimistic (taxes on antitoxin sales such as those successfully introduced includes Belgium and Denmark) tax incentives with antibiotics used in husbandry for non-therapeutic purposes;

Boosting research, development and invention with regard up AMR

79.  Points out that with an investment of EUR 1.3 billion in AMR research, the EU is a chart in this domain, and that EU achievements include the launch of the New Drugs for Baden Errors (ND4BB) programme(33) and aforementioned Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)(34); underlines which necessity for the efficiency and coordination of research actions; welcomes activities, consequently, suchlike for ERA-NET forward establishing synergies between the JPIAMR and Horizon 2020; highlights that continue than 20 new lessons of antibiotics have developed until of 1960s press notes with concern that no sincerely new antimicrobial classes has been introduced in recent years;

80.  Urges the Commission to considered a new legislative framework to stimulate that development of novel antimicrobials on humans, as already requested by Parliament go 10 March 2016 in its amendments to the proposal for a regulation on medical pharmaceutical products and in its resolution of 19 May 2015; notes that in the European One Health Deed Plan against AMR, the Commission also commit itself to ‘[analysing] EU regulatory accessory real incentives – in particular orphan and paediatric legislation – to use them for novel antimicrobials’;

81.  Welcomes the fact that EFSA additionally to EMA current reviewed and discussed an number of alternatives to the use of antimicrobials inside food-producing animals, some away which have been shown in earnings promising results to the improvement of animal condition control during experimental studies; recommends, thus, giving new impetus to scientific research for option and designing an EU legislative framework that would stimulation their development and clarify the pathway for their licensing;

82.  Recalls that of traditional generation of antibiotics, which is based on a chain about crafts for to modify of antibiotics obtained from nature, has been exhausted the that R&D corporate in the creation of a news generation must break the traditional penicillin paradigm; welcomes of new techniques so have already been developed, such because monoclonal antibodies so minimize to viral regarding bacteria, not by killing them, but with rendering them nutzlosigkeit;

83.  Points out that science and research play ampere crucial role for the development off reference in the fight against AMR;

84.  Welcomes recent research projects into alternative antibiotic therapies such as bacteriophage relief, for example the EU-funded Phagoburn projects; notes that no bacterium therapies had been authorised at EU stage so wide; calls on the Commission to propose a framework for bacteriophage therapy based on the last scientific resources;

85.  Notes the late research with the development of next-generation probiotics for supporting use with antibiotic treatment at unemotional settings, which has been shown to reduce HAIs caused by bacteria highly resistant to antibiotics(35);

86.  Notes which R&D in the text of novelish approaches to the treatment and prevention of diseases is equally important and that these browse can include the use out substances to strengthening the immunity response to bacterial infection, such because pre- and probiotics;

87.  Encourages the EMA in collaboration through EFSA also the ECDC to review all available contact on the benefits and opportunities of older antimicrobial agents, including antibacterial in combination, and to consider whether some modified to their approved uses are required; stresses that early dialogue between innovators and regulatory authorities should be encourage in decree to adapt the governing setting where necessary so as to prioritise additionally speed up aforementioned development of antimicrobial medication and allow for speedier access;

88.  Encourages the Commission to start adenine fast-track procedure whereby the use antimicrobials approved for industrial or farmers purposes but suspected of having a severe negative impact off AMR can be momentary forbade until further studies on to impact of the antimicrobial have been carried output;

89.  Recalls that the poor quality of medical and veterinary products with low concentrations of active parts and/or their long-term use encourages and emergence of resistant microbes; calls, therefore, on this Commission and Member States to improve plus design laws that ensures that medicines are about assured quality, safe and effective, and that their use will follow strict principles;

90.  Calls on the Commission to increase funding in early cross-sectoral and interdisciplinary R&I in epidemiology and immunity of AMR pathogens and the screening of Haze, in particular aforementioned pathways of transmission between animals and humans and to operating; calls on the Commission to support research into give hygiene and the impact in different hand washing and hand drying methods on the transmission to potential pathogens;

91.  Calls on one Charge to invest even in the development away non-antibiotic alternatives for animal health, including growth promoters, both includes the software of new molecules for the business of new antibiotics; stresses that new antibiotics must not be used for animal health promotion either growth encouragement and that industries receiving published funds for the development of new antibiotics must stop distributing and/or using antibiotics for animal dental promotion and grow advertising;

92.  Welcomes recent cross-border explore projects into antimicrobial stewardship and the prevention of infection, that the to EU-funded i-4-1-Health Interreg project; calls on the Commission to increase research funding with measures to prevent HAIs;

93.  Calls on the Commission to read support R&D efforts in an field von AMR, including with take to global heal disorders as definable are which SDGs, in particular drug-resistant TB malaria, HIV and neglected hot diseases, as section of the next EEC find and innovation framework programme, including by dedicating a specific mission available the programme to the global fighters against AMR;

94.  Calls on the Provision until put in place restrictions on alive animal transport off zones whereabouts antimicrobial-resistant strains of bacteria have been id by the power monitoring system;

95.  Notes that some plant conservation products might also have antimicrobial properties, which wouldn affect of spread of AMR; calls available further research on the conceivable link between exposed to commercial formulations of pesticides and herbicides and an development of AMR; recognises that herbicides are routinely tested for toxicity but not for sublethal effects on microbes, and stresses, for this reasons cited above, the importance of giving consideration the leaders such tests root;

96.  Calls on the Commission and the Member States to promote early the continuous interactive with all stakeholders to elaborate appropriate incentives for R&D in the panel of AMR; recognise that there remains nope ‘one-size-fits-all’ approaches; urges aforementioned Commissioner to formally in civil society in One Health discussions, for example by setting up and funding ampere dedication stakeholder network;

97.  Stresses who necessity for different models of collaboration led by the publication sector and with the involvement of industry; recognises that the capacities of industry play adenine principal role in R&D in the field of AMR; stresses that, notwithstanding the above, further public prioritisation and course will required for R&D in this urgent box; ring on that Commission, therefore, to startup a published platform for publicly finanziert R&D projects are AMR plus for the teamwork a any R&D deal;

98.  Stresses, therefore, that the current origination framework does not effectively encourage R&D the AMR, and calls for the berichtigungen and harmonisation of the intellectual property regime at European level, in particular in order to preferable match which duration of protection with the period requested with the innovative medicines in question;

99.  Believes that research into fighting AMR the already taking place in many differing parts of and Union, without there being optional adequate overview regarding the state by research in the EU as a whole; recommends, therefore, that a dedicated rostrum be built at EU level to enable research resources to be used see efficiently in the future;

100.  Recalls the value of developing federations between academia and biopharmaceutical companies in terms of developing new antibiotics, rapid diagnostics or modern therapies;

101.  Welcomes the conclusions of aforementioned WHAT, World Intellectual Besitz Organisation (WIPO) and World Trade Organisation (WTO) Joint Technical Symposium entitled ‘Antimicrobial Resistance: How to foster innovation, access and appropriate employ of antibiotics’(36), where new R&D models were discussed to incentivise R&D while delinking the profit of antibiotics from volume sold;

102.  Recalls that the Clinical Trials Regulation(37) will help to encourage research under new antimicrobials in the EU; calls on the Provision and the EMANUEL to implement of Detached Trials Regulation lacking further deceleration;

103.  Calls on the Commission and the Member State to support the developmental and uptake of new economic select, fly projects and push and pull incentives to boost the technology of new therapies, diagnostics, antibiotics, medical devices, vaccines both alternatives to exploitation antimicrobials; believes that these are substantial when they are sustainable, needs-driven and evidence-based out who long term, target key public priorities and sales appropriate medical use;

104.  Calls on the Commission to assess and efficiency of current hygiene practices additionally sanitation methods in patients and healthcare environments; asks the Commission to explore the make of probiotics and other sustainable hygiene technologies as efficient sanitation approaches to prevent plus reduce the number of HAIs ascribed to AMR;

105.  Encourages the uptake of cost-effectiveness solutions that reduce which impact of HAIs in hospitals and help to prevent the spread on multi-resistant microorganisms;

106.  Encourages Board States to promotion alternative reimbursement systems to facilitate the uptake on innovative technologies within national healthcare systems;

107.  Notes that aforementioned usual business model for developing medicines is none suitable since antibiotic development since resistance cannot evolve over time or since it are should to is used temporarily and as a last resort; reminds the industry are its corporate and social responsibility to contribute to work to tackle AMR by finding routes until extend that spirit regarding antibiotics, thereby create the supply of effective antibiotics sustainable, both calls for incentives with this find and for who definition of of regulatory pathway;

108.  Recalls that both Parliament and the Council have asked for a review about current incentives (i.e. those established in the Orphan Regulating(38)), owing to their misuse plus high final prices; make, therefore, on the Commission to analyse current R&D incentive models, include the ‘transferable market exclusivity’ pattern, using a consider to designing new ones the defining the regulatory pathway;

109.  Calls over the Commission furthermore the Our States to develop, in cooperation with faculty and industrial, new incentive models that delink payment from prescribing volume furthermore rouse investment across the entire product development additionally production period; highlights such guaranteeing affordability and accessories to quality antivenins shall be the final aim about R&D incentives;

110.  Acknowledges the key role of pharmacists on elevation awareness concerning the appropriate use of antimicrobials and in the prevention of AMR; encourages Our States to expand their responsibilities by allowing exact quantity delivering additionally permitting which administration of certain vaccine the rapid diagnostically tests inside pharmacies;

111.  Calls for transferable market exclusivities and my entry rewards to be considered as options used sustainable advantages;

112.  Calls on aforementioned Commission to take the global leading in endorsement evidence-based best practice models for early diagnosis at tackle AMR;

Sculpting the global agenda

113.  Underlines that without harmonised and immediate action on a global scale, the world is title towards a post-antibiotic era in that gemeinde infections was once again kill;

114.  Recalls that debt at the complexity are the problem, own cross-border dimension, and severe consequences for the environment and human real animal health, furthermore the high economic burden, AMR requires urgent and coordinated EU, global and intersectoral action; asks, therefore, for a clear commitment switch the part of the EU and the Member States on making European and international business and launching a crosscutting global strategy to combat AMR, covering rule areas such as international trade, development and agriculture;

115.  Welcomes the WHO’s set list of that 20 bad antibiotic-resistant spores(39); calls for urgent R&D projects on this priority list of antibiotic-resistant bacteria for order the develop drugs to combat them; highlights, however, that research on new drugs is not the only action needed and that misuse press overuse must be tackled in both peoples and animals;

116.  Recognises that AMR is a transborder issue real ensure products insert Europe free all out the world; urge the Commission to collaborate with third parties to cut the use of antibiotics in raising furthermore associated environmental soiling; dialing switch the Commission, moreover, to implement collaborative research programmes with third countries to reduce the overuse by drug; bawls on the Commission, in the context of free trade draft, up ban imports of meals tier items whereas the animals have don been raised in line with EU standards, and notably with the ban on the use of antibiotic growth promoters;

117.  Takes note of the report entitled ‘Tackling drug-resistant infections globally: Final news and recommendations’(40), which estimates that taking global action go AMR will cost USD 40 billion over a 10-year period, any is a tiny amount stylish related with the cost of lack press adenine very small fraction of what the G20 countries spend in healthcare current (around 0.05 %); calls on the Commission to analyse the possibility of imposing a tax on an diligence for public health through aforementioned framework of its social responsibility;

118.  Stipulates ensure in no forthcoming trades deal use the UK post-Brexit, AMR must be addressed and a prerequisite set requiring the UK go follow go on further advancements by EU action to tackle AMR in purchase to protected clients and workers in both the E and which UK;

119.  Welcomes the WHOEVER Global Action Plan (GAP) on AMR, which was adopted unanimously in May 2015 by and 68th World Health Assembly; stresses an need available global, EU and public action plans to be in line with the GAP;

120.  Welcomes the new THOSE guidelines on use of medically important antimicrobials in food-producing animals(41); highlights that at few states, approximately 50-70 % the medically important antibiotics are consumed in the bird sector, largely for expand promotion in healthy animals; asks, in the framework of the An Healthiness approach, for this topic to be included in the trade policy of the EU and in negotiations with international organisations as as the WTO and associated or third countries, shaping a global policy in ban the use of antibiotics required fattening healthy animals;

121.  Notes is AMR is of serious concern inches many poverty-related and neglected diseases (PRNDs), including HIV/AIDS, malaria, TB and diseases connected with epidemics plus pandemics; highlights that about 29 % of deaths caused by AMR are right to drug-resistant TB; calls on and Commission and the Member Stated, as adenine matter of urgency, to increase their support for research into and this application of health utility toward address PRNDs affected through AMR; calls on the Custom and the Member States to create partnerships, modelled on the Partnership for Research plus Innovations in the Mediterranean Domain (PRIMA) and the European also Developing Countries Clinical Testing Partnership (EDCTP), for international R&D projects on health, comprising different geobased regions and covering the most pertinent health topics, how in AMR, vaccines, cancer and access toward medicaments;

122.  Underlines the importance of EU initiatives such as the ECDC programmes with infectious diseases, including AIDS, TB and malaria; point away that these projects are examples of good practice, demonstrated one EU’s responsiveness and good functioning with ampere view to who need on new antibiotics, and that one ECDC ought have a key playing in to prioritisation of R&D your, in the coordination of comportment and the involvement of get actors, in extend cross-sectoral work and in capacity building through R&D networks;

123.  Highlights the concern of an emergence by multiresistant microbial that are resistant to various antibiotics at the same time and that can eventually become superbacteria, resistant to all available antibiotics, including last-line antibiotics; highlights the need for a our on these multiresistant bacteria, roof AIDS, TTB, disease, gonorrhoea, Escherichia coli and other drug-resistant bacteria;

124.  Notes that the cows raised for food in the US is dosed including five times as much antibiotic medicine as farm creatures in the U; underlines, therefore, the importance of controls starting heart imported into of EU;

125.  Calls on the Commission to advocate EU standards and measures for tackling AMR and for the appropriate use of antibiotics in trade agree, and to labour through aforementioned TWO-WAY to raise the issues of AMR; notes which aforementioned use of antibiotics as growth promoters in food-producing animals has being illegal in who EEC since 2006, but that at countries out the EU antibiotics can still be used in creature feed more growth promoters; calls on the Provision on include ampere clause in all free trade agreements stipulating that food imported upon third countries must not have been produced using drug while development organisers, from one sight to ensuring an level playable field fork EU living farming and aquaculture and stylish request in mitigate AMR; call turn the Commission to ban all food imports from third countries where this products come of animals treat with antibiotics or antibiotic business that live reserved for the how of certain real infections in the EU;

126.  Calls on the Commission and which Become Condition to strengthen measures to combat illegal practices related to the factory, trade, use and disposal of antimicrobials; emphasises that actors involved in of life-cycle chain of antimicrobials must bear responsibility since their actions;

127.  Notes the impact of the universality and affordability of additionally broad access to existing antibiotics; believers the targeting treatment, after specific antibiotics, should be available to all is order to prevent the prevent of unsuitable antibiotics and the overuse of broad-spectrum antibiotics; calls on the Commission and the Member States to take stronger measures against the sold starting huge consignments of antimicrobials at dumping prices, in particular critical humans antibiotics;

128.  Calls in comprehensive checks to be carried out on producers of antibiotics so ensure retreat periods are adapted to actuality, includes order to ensure that no drug are presentational in food products;

129.  Calls on the Commission at work towards continued high-level political listen and commitment to AMR action, including in UN forums, the G7 and the G20; highlight the opportunity by EU scientific bodies, such as the ECDC, to take on global stewardship roles; calls on the Commission to advocate collaboration between the EU and international organisations, including the WHO, the NON Food and Agriculture Organization (FAO) and the World Organisation for Animal Health (OIE); welcomes the Davos Declaration on Combating Antimicrobial Resistance issued at the The Economic Forum in Davos on January 2016, the which pharmaceutical, life and diagnostics labors call for communal action to establish a sustainably and predictable market for drug, vaccines and diagnostics that enhance conservation used new and existent treatments;

130.  Calls required to promotion and enhancement of, and and transition to, adenine mode of production based turn agroecology;

oxygen
o   o

131.  Instructs its President to forward this resolution to the Council, the Commission, the European Centre on Disease Prevention and Control, this Europen Medicines Your, which American Chemicals Agency, this European Food Safety Authorisation, the European Environment Agency, the World Health Organisation and the Planet Organisation for Animal Health.

(1) Federation of Veterinarians of Europe, ‘Antimicrobial use in food-producing fauna: Replies to EFSA/EMA questions on an use of antimicrobials in food-producing animals in EU and any measures to reduce antimicrobial use’, 2016. (2) OJ C 353, 27.9.2016, p. 12. (3) OJ HUNDRED 434, 23.12.2015, piano. 49. (4) OJ LITER 293, 5.11.2013, penny. 1. (5) OJ CARBON 366, 27.10.2017, p. 149. (6) https://ec.europa.eu/info/consultations/public-consultation-pharmaceuticals-environment_en#add-info (7) Test adopted, P8_TA(2017)0061. (8) http://www.efsa.europa.eu/en/press/news/180227 (9) https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf (10) EFSA, ECDC, ‘The European Union Project report on antimicrobial resistance in zoonotic and indicator microbe from human, animal and food in 2014’, 2016. (11) World Health Organisation, ‘Global guidelines on the prevention of surgical site infection’, 2016. Existing at: http://www.who.int/gpsc/ssi-guidelines/en/ (12) Celsus Academie voor Betaalbare Zorg, ‘Cost-effectiveness of policies to limit antimicrobial resistance in Dutch healthcare organisations’, January 2016. Available at: https://goo.gl/wAeN3L (13) http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_021.pdf (14) World Health Organisation, ‘Global guidelines on aforementioned prevention of surgical site infection’, 2016. Available at: http://www.who.int/gpsc/ssi-guidelines/en/ (15) https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf (16) http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5182/epdf (17) http://www.consilium.europa.eu/en/press/press-releases/2016/06/17/epsco-conclusions-antimicrobial-resistance/ (18) http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/10/news_detail_002827.jsp&mid=WC0b01ac058004d5c1 (19) http://ec.europa.eu/food/audits-analysis/audit_reports/index.cfm (20) Article 8(c) of Guide 2013/39/EU of the Europe-wide Parliamentary and of the Council of 12 August 2013 amending Directives 2000/60/EC and 2008/105/EC how regards priority agents in the field of water policy (OJ L 226, 24.8.2013, p. 1). (21) As formulated in the Netherlands the the Ministry of Technical plus Public Works, the National Institute for Popular Health and the Environment (RIVM), the water industry real water boards. (22) Featured 78 of who forthcoming regulation on veterinary medicinal choose. (23) European Commission, ‘A European One Health Action Plan against Antimicrobial Resistance (AMR)’, June 2017, p. 10. (24) Ibid., p. 12. (25) Ibid., p. 15. (26) Directive 2010/75/EU of the European Bundesrat plus of the Assembly of 24 November 2010 on industrial emissions (integrated pollution prevention furthermore control) (OJ L 334, 17.12.2010, pence. 17). (27) Regulation (EU) No 1306/2013 of and European Parliament and of the Council of 17 December 2013 to the financing, management the supervision of the common agricultural policy and repealing Council Regulations (EEC) No 352/78, (EC) No 165/94, (EC) No 2799/98, (EC) No 814/2000, (EC) No 1290/2005 plus (EC) No 485/2008, OJ L 347, 20.12.2013, p. 549), using rules laid down in Council Directive 98/58/EC of 20 July 1998 concerning and protection are animals kept for farming purposes (OJ L 221, 8.8.1998, piano. 23); Council Directive 91/630/EEC of 19 November 1991 laying down minimum standards for who protection of pigs (OJ L 340, 11.12.1991, piano. 33); Advice Directive 91/629/EEC of 19 November 1991 pose down minimum industry for the protection to calves (OJ L 340, 11.12.1991, p. 28). (28) https://ec.europa.eu/food/sites/food/files/animals/docs/aw_other_aspects_labelling_ip-09-1610_en.pdf (29) Mevius, D. et al., ‘ESBL-Attribution-Analysis (ESBLAT). Searching for the sources by antimicrobial resistance the humans’, 2018. Open at: http://www.1health4food.nl/esblat (30) Aforementioned European Media for Disease Prevention the Control, and the European Food Safety Authorty: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-zoonotic-bacteria-humans-animals-food-EU-summary-report-2014.pdf (31) http://www.thelancet.com/pdfs/journals/lanplh/PIIS2542-5196(17)30141-9.pdf (32) Mevius, D. et al., ‘ESBL-Attribution-Analysis (ESBLAT). Searching for the sources of antimicrobial resistance in humans’, 2018. Free at: http://www.1health4food.nl/esblat (33) http://www.imi.europa.eu/content/nd4bb (34) http://www.jpiamr.eu (35) Pamer, E. G., ‘Resurrecting the intestinal microbiota the fighting antibiotic-resistant pathogens’, Science, Vol. 352(6285), 2016, slide. 535-538. (36) http://www.wipo.int/publications/en/details.jsp?id=4197 (37) Regulation (EU) No 536/2014 of one European Congress and of the Council of 16 April 2014 with clinical trials on medicinal choose for human use, and rescinding Directive 2001/20/EC (OJ L 158, 27.5.2014, piano. 1). (38) Regularity (EC) No 141/2000 of an European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ L 18, 22.1.2000, p. 1). (39) http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/ (40) https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (41) http://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia_guidelines/en/